Biogen Inc (BIIB)

HEALTH CARE: PHARMACEUTICALS
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

225 BINNEY STREET CAMBRIDGE, MA 02142

Biogen Idec Inc. (Biogen Idec) is a global biotechnology company. The products of the Company include AVONEX, RITUXAN, TYSABRI and FUMADERM. The Company's products address diseases, such as multiple sclerosis (MS), non-Hodgkin's lymphoma (NHL), rheumatoid arthritis (RA), Crohn's disease (CD) and psoriasis. In addition to the marketed products, Biogen Idec has a number of product candidates in or near registrational stage development. It includes BG-12, Daclizumab, Fampridine, GA101, Humanized Anti-CD20 MAb (ocrelizumab), Lixiavaptan, Long-Acting rFactor IX and PEGylated interferon beta-1a. In December 2010, the Company and Neurimmune Holding AG announced that the Company had acquired a subsidiary of Neurimmune Holding AG.

Data as of 2021-01-16
Market Cap42.447 Billion Shares Outstanding153.882 Million Avg 30-day Volume1.317 Million
P/E Ratio9.1 Dividend Yield EPS30.2
Price/Sales4.007 Price cash flow ratio7.0 Price free cash flow ratio11.9
Book Value69.91 Price to Tangible Book25.28 Alpha-0.01
Short Interest Ratio % Short Interest to Float R-squared0.059016
BETA0.513279 52-week High/Low374.99 / 223.25 Stddev0.092972
View SEC Filings from BIIB instead.
Q3 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 16 21 -23.81% 16 (1.05%) 13 (0.84%) 23.08%
Funds Holding: 1012 1030 -1.75% 212 (13.94%) 220 (14.28%) -3.64%
13F shares: 128.733 Million 133.175 Million -3.34% 31.763 Million 33.327 Million -4.69%
% Ownership 81.3154 84.1214 -3.34% 20.0635 21.0512 -4.69%
New Positions: 94 94 0.0% 19 24 -20.83%
Increased Positions 302 328 -7.93% 62 67 -7.46%
Closed Positions 87 127 -31.5% 25 23 8.7%
Reduced Positions 416 431 -3.48% 94 96 -2.08%
Total Calls 4.465 Million 2.999 Million 48.86% 1.543 Million 749.604 Thousand 105.8%
Total Puts 4.978 Million 4.873 Million 2.17% 1.733 Million 1.686 Million 2.82%
PUT/CALL Ratio 1.12 1.62 -30.86% 1.12 2.25 -50.22%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding BIIB (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding BIIB BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

3.1 Thousand total shares from 1 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

555 total shares from 2 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

KRAMER ROBIN VP, CHIEF ACCOUNTING OFFICER

  • Officer
373 2020-12-03 3

GUINDO CHIRFI EVP GLOB. PROD STRAT AND COMM

  • Officer
3,790 2020-12-01 2

VOUNATSOS MICHEL CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
34,810 2020-11-30 3

SANDROCK ALFRED EVP, RESEARCH & DEVELOPMENT

  • Officer
13,066 2020-11-04 3

MCDONNELL MICHAEL R EVP, CHIEF FINANCIAL OFFICER

  • Officer
0 2020-09-01 2

GREGORY GINGER EVP, HUMAN RESOURCES

  • Officer
4,691 2020-07-31 2

POSNER BRIAN S

  • Director
7,885 2020-06-03 1

LEAMING NANCY

  • Director
12,988 2020-06-03 1

SHERWIN STEPHEN A

  • Director
16,328 2020-06-03 2

ROWINSKY ERIC K

  • Director
17,069 2020-06-03 1

PANGIA ROBERT W

  • Director
20,632 2020-06-03 1

DENNER ALEXANDER J

  • Director
655,954 2020-06-03 1

DORSA CAROLINE

  • Director
21,097 2020-06-03 1

PAPADOPOULOS STELIOS

  • Director
34,771 2020-06-03 1

MULLIGAN RICHARD

  • Director
12,954 2020-06-03 1

MANTAS JESUS B

  • Director
2,045 2020-06-03 1

HAWKINS WILLIAM A

  • Director
2,045 2020-06-03 1

ALEXANDER SUSAN H EVP CHIEF LEGAL OFF & CORP SEC

  • Officer
36,572 2020-02-15 2

GALDES ALPHONSE EVP PHARMACEUTICAL OPER & TECH

  • Officer
3,512 2020-02-15 2

CAPELLO JEFFREY D EVP & CHIEF FINANCIAL OFFICER

  • Officer
3,118 2020-02-12 1

KARP DANIEL EVP, CORPORATE DEVELOPMENT

  • Officer
930 2020-02-12 1

SCHENK LYNN

  • Director
12,132 2019-06-19 0

EHLERS MICHAEL D EVP, RESEARCH AND DEVELOPMENT

  • Officer
8,025 2019-06-01 0

MCKENZIE PAUL EVP PHARMACEUTICAL OPER & TECH

  • Officer
7,235 2019-03-01 0

COVINO GREGORY F VP, CHIEF ACCOUNTING OFFICER

  • Officer
0 2018-03-01 0

KRESS JEAN-PAUL EVP PRES INT'L & GLOBAL HD GTO

  • Officer
0 2017-07-03 0

CLANCY PAUL J EXECUTIVE VP AND CFO

  • Officer
10,813 2017-04-25 0

DIPIETRO KENNETH EVP HUMAN RESOURCES

  • Officer
7,177 2017-02-28 0

KARABOUTIS ADRIANA EVP, TECH, BUS. SOL & CORP AFF

  • Officer
8,752 2017-02-28 0

SCANGOS GEORGE A CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
65,535 2016-07-21 0

KOPPEL ADAM EVP, STRATEGY AND BUS. DEV.

  • Officer
No longer subject to file 2016-06-06 0

ARTAVANIS-TSAKONAS SPYRIDON EVP, CHIEF SCIENTIFIC OFFICER

  • Officer
3,150 2016-04-02 0

COX JOHN EVP PHARMACEUTICAL OPER & TECH

  • Officer
39,045 2016-04-01 0

HOLTZMAN STEVEN H EVP CORPORATE DEVELOPMENT

  • Officer
No longer subject to file 2016-02-23 0

WILLIAMS DOUGLAS E EVP RESEARCH & DEVELOPMENT

  • Officer
11,817 2015-06-19 0

KINGSLEY STUART A EVP, GLOBAL COMM. OPERATIONS

  • Officer
0 2015-02-23 0

YOUNG WILLIAM

  • Director
18,509 2014-01-08 0

PAWLICKI RAYMOND SVP, CHIEF INFORMATION OFFICER

  • Officer
8,710 2013-11-22 0

GAGNON ROBERT E. VICE PRESIDENT, FINANCE

  • Officer
3,999 2012-02-28 0

GRANATA FRANCESCO EVP GLOBAL COMMERCIAL OPERATIO

  • Officer
3,529 2012-02-01 0

SCHNEIER CRAIG ERIC EVP, HR, PUBLIC AFFAIRS & COMM

  • Officer
10,661 2011-03-01 0

MACLEAN MICHAEL F SVP, CHIEF ACCOUNTING OFFICER

  • Officer
10,681 2010-10-01 0

MULLEN JAMES C CEO & PRESIDENT

  • Officer
  • Director
No longer subject to file 2010-06-08 0

ROSS BRUCE

  • Director
No longer subject to file 2010-06-08 0

HAMM ROBERT A CHIEF OPERATING OFFICER

  • Officer
27,212 2010-04-23 0

LYTTON MICHAEL EVP CORPORATE & BUSINESS DEVEL

  • Officer
18,869 2010-03-02 0

PICKETT CECIL B PRESIDENT, R & D

  • Officer
  • Director
No longer subject to file 2009-10-02 0

SHARP PHILIP A

  • Director
470,278 2009-06-03 0

DEKKERS MARIJN E

  • Director
6,595 2009-06-03 0

HASLER HANS PETER CHIEF OPERATING OFFICER

  • Officer
53,261 2009-02-24 0

DUNN JOHN MICHAEL EVP, NEW VENTURES

  • Officer
No longer subject to file 2009-02-24 0

WIGGINS MARK C EVP CORP. AND BUS. DEV.

  • Officer
22,780 2008-09-26 0

HASNAIN FAHEEM EVP, ONCOLOGY/RHEUMATOLOGY SBU

  • Officer
25,454 2008-07-09 0

GLASSBERG ALAN

  • Director
5,600 2008-06-19 0

BEST LAWRENCE C

  • Director
5,600 2008-06-19 0

KELLER THOMAS F

  • Director
1,250 2007-10-15 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

KRAMER ROBIN - Officer VP, CHIEF ACCOUNTING OFFICER

2020-12-07 21:08:59 -0500 2020-12-03 M 74 d 280 direct

KRAMER ROBIN - Officer VP, CHIEF ACCOUNTING OFFICER

2020-12-07 21:08:59 -0500 2020-12-03 F 22 $244.09 d 373 direct -0.6817 0.9333 9.3373 13.7402 26 -2.029 4

KRAMER ROBIN - Officer VP, CHIEF ACCOUNTING OFFICER

2020-12-07 21:08:59 -0500 2020-12-03 J 102 d 178 direct

KRAMER ROBIN - Officer VP, CHIEF ACCOUNTING OFFICER

2020-12-07 21:08:59 -0500 2020-12-03 M 74 a 395 direct -0.6817 0.9333 9.3373 13.7402 26 -2.029 4

GUINDO CHIRFI - Officer EVP GLOB. PROD STRAT AND COMM

2020-12-03 17:41:07 -0500 2020-12-01 J 693 d 0 direct

GUINDO CHIRFI - Officer EVP GLOB. PROD STRAT AND COMM

2020-12-03 17:41:07 -0500 2020-12-01 M 481 a 4,004 direct -0.8907 -1.8058 9.928 13.9993 28 -1.8058 6

GUINDO CHIRFI - Officer EVP GLOB. PROD STRAT AND COMM

2020-12-03 17:41:07 -0500 2020-12-01 M 481 d 693 direct

GUINDO CHIRFI - Officer EVP GLOB. PROD STRAT AND COMM

2020-12-03 17:41:07 -0500 2020-12-01 F 348 $243.16 d 3,523 direct -0.8907 -1.8058 9.928 13.9993 28 -1.8058 6

GUINDO CHIRFI - Officer EVP GLOB. PROD STRAT AND COMM

2020-12-03 17:41:07 -0500 2020-12-01 F 214 $243.16 d 3,790 direct -0.8907 -1.8058 9.928 13.9993 28 -1.8058 6

VOUNATSOS MICHEL - Director - Officer CHIEF EXECUTIVE OFFICER

2020-12-01 16:57:29 -0500 2020-11-30 P 3,100 $241.31 a 34,810 direct -1.1461 -0.8788 11.7123 13.5145 30 -2.2234 8

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments